Navigation Links
Vermillion's Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
Date:5/1/2008

nd uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize its PAD diagnostics products in 2008 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize PAD diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop PAD diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its PAD diagnostic products; (5) uncertainty of market acceptance of its PAD diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; and (6) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisio
'/>"/>
SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
2. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. VNUS Medical Technologies to Report Third-Quarter 2007 Results and Webcast Teleconference on October 29
5. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
6. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
7. WorldHeart Schedules Teleconference
8. VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7
9. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
10. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
11. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... , SAN CARLOS, Calif., Sept. 21 Nektar Therapeutics ... call to discuss today,s announcement of a new partnership for NKTR-118 and NKTR-119. ... Time (PT). , , The live audio-only Webcast of the ... home page of Nektar,s website: http://www.nektar.com . The web broadcast ...
... , LONDON and SAN CARLOS, ... announced today that they have entered into an exclusive worldwide ... stage investigational product being evaluated for the treatment of opioid-induced ... is intended to deliver products for the treatment of pain ...
... FreezerPro ... and Liquid Nitrogen Tank samples and efficiently manage data of any kind associated with ... ... of FreezerPro 2010, Frozen sample inventory and information management system (FSIIMS). FreezerPro 2010 is ...
Cached Biology Technology:Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119 2AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 2AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 3AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 4AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 5RURO Inc. Today Announced the Release of FreezerPro 2010, Frozen Sample Inventory and Information Management System 2
(Date:4/22/2014)... how communities can protect themselves from worsening storms. ... New England and the Midwest providing practical and ... goal is to help communities begin the steps ... of Syntectic International, Portland, OR. "It,s important because ... beyond feeling paralyzed from the lack of local ...
(Date:4/21/2014)... is commonly used as a farm soil fertilizer, contains ... from the cows, gut bacteria. The findings, reported in ... American Society for Microbiology, hints that cow manure is ... genes that transfer to bacteria in the soils where ... (AR) genes have already been identified, but the vast ...
(Date:4/21/2014)... in the Galpagos. , A new study appearing in the ... the iconic birds, known for their bright blue feet and ... more than 50 percent in less than 20 years. ... an unexplained disappearance of sardines from the Boobies, diet, said ... and the study,s principal investigator. This in turn has adult ...
Breaking Biology News(10 mins):Minnesota projects offer hope and practical help to communities facing more extreme storms 2Cow manure harbors diverse new antibiotic resistance genes 2Cow manure harbors diverse new antibiotic resistance genes 3Lack of breeding threatens blue-footed boobies' survival 2Lack of breeding threatens blue-footed boobies' survival 3
... Clinic biochemist George R. Stark, Ph.D., has been awarded ... 2011 Herbert Tabor/ Journal of Biological Chemistry Lectureship. ... Cleveland Clinic,s Lerner Research Institute and Emeritus Professor of ... has been a leader and pioneer in basic and ...
... NY, April 3, 2011) In the largest study of ... Medical Center identified four new genes linked to late-onset Alzheimer,s ... developing this most common form of the disease, and together ... identification will help researchers find ways to determine who is ...
... newborn neurons in their brain memory hub excelled at ... declines with normal aging and in some anxiety disorders. ... antidepressant-like effects when combined with exercise, in the study ... Researchers, for the first time, pinpointed the effects ...
Cached Biology News:Researcher receives lectureship for lifetime achievements 2Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 2Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 3Nurturing newborn neurons sharpens minds in mice 2
...
... M(1) E F L P E P Q ... D L E(19) PA1-072 detects munc-18 interacting protein ... used in Western blot procedures. By Western ... representing Mint3 from AtT20 cell extract.,PA1-072 immunizing peptide ...
... Receptor (AR) Competitor Assay Kits provide a ... screening potential AR ligands using fluorescence polarization ... binding domain protein tagged with His and ... fluorescent androgen ligand (Fluormone AL Green in ...
... cost-effective solutions for complex protein processing and production challenges. ... to help you develop a solution to your problem ... , do additional ... transfer all methodology to your own lab ...
Biology Products: